What 4baseCare does

4baseCare Precision Health Private Limited is a Bengaluru-headquartered precision oncology company founded in 2019 by Hitesh Goswami (CEO) and Kshitij Rishi (COO). The company delivers AI-powered genomics solutions for cancer diagnosis, treatment selection, and clinical trial optimization, operating hospital-linked genomics laboratories across India, Dubai, Nepal, and the Philippines. Its core technology stack combines next-generation sequencing (NGS) with the proprietary OncoTwin AI platform, which creates digital twins of cancer patients by integrating genomic, pathology, radiology, and clinical data to support clinical decision-making, molecular tumor boards, and biomarker discovery.

The product portfolio spans five genomic test modalities (tissue profiling, liquid biopsy/ctDNA, SoLiQ dual-source, HRD/PARPredict, and germline testing), the Global Cancer Diversity Atlas (30,000+ genomic profiles from 15+ countries covering 70+ cancer types, with a stated focus on underrepresented Asian, Middle Eastern, and Southeast Asian populations), the OncoBuddy patient community platform, and patient access initiatives including the LuNGS Alliance (free NGS testing for lung cancer patients, covering 6,600+ patients across 700 cities) and the Hope Initiative with AIIMS Jammu. The company is an Illumina Accelerator portfolio company and was selected for the Memorial Sloan Kettering iHub Challenge 2025 Cohort.

4baseCare's revenue model combines fee-for-service genomic testing sold to hospitals and oncologists with platform licensing for OncoTwin to pharma companies and research institutions. GTM is enterprise field sales through hospital partnerships and lab collaborations, with a stated target of establishing 25 new lab collaborations and entering 8-10 additional countries within 12-18 months. Customer base includes hospital partners (Max Healthcare, AIIMS Jammu, Shankara Hospital, Caritas Hospitals), global pharma (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer, Roche via LuNGS Alliance), and emerging Tier-2/Tier-3 city hospitals. The company has been revenue-positive for five years with approximately ₹40 Cr in disclosed annual revenue, a ₹100 Cr revenue target for the next 12-18 months, and ₹130 Cr in Series B funding closed in 2026 at a ₹130 Cr post-money valuation.

Name

4baseCare

Legal name

4baseCare Precision Health Private Limited

Website

https://4basecare.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

4baseCare is a precision oncology company that combines NGS-based genomic testing with the OncoTwin AI platform and a Global Cancer Diversity Atlas to deliver AI-powered cancer treatment decision support, serving hospitals, oncologists, and pharma companies across India, the Middle East, Southeast Asia, and emerging markets.

Ownership category

akta.pro rank

Product category

Cancer Genomics Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)

akta.pro secondary industries

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Precision oncology solutions
• Genomic profiling services
• Cancer diagnostics platform
• AI clinical decision support
• Liquid biopsy testing

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Genomic Testing Services: Revenue generated from comprehensive genomic profiling tests including tissue profiling, liquid biopsy, SoLiQ dual-source testing, HRD testing, and germline cancer risk testing. Sold directly to hospitals and healthcare providers through partnerships.
2. AI Platform Services: OncoTwin AI platform licensing for clinical decision support, molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharma companies.
3. Laboratory Services: Hospital-linked genomics laboratory services through partnerships. Labs established in India, Dubai, Nepal, and Philippines provide diagnostic services.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

4baseCare delivers precision oncology through two integrated lines: (1) comprehensive genomic profiling tests (tissue, liquid biopsy/ctDNA, SoLiQ dual-source, HRD/PARPredict, and germline testing) performed in its hospital-linked genomics laboratories across India, UAE, Nepal, and the Philippines, and (2) the OncoTwin AI platform that creates digital twins of cancer patients by integrating multi-modal data to support clinical decision-making, molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharmaceutical companies.

Product overview

4baseCare is a precision oncology company offering an integrated platform of genomics-based cancer diagnostics and AI-powered solutions. The portfolio centers on OncoTwin (AI-powered digital twin platform for treatment decisions), comprehensive Genomic Tests (tissue, liquid, SoLiQ, HRD, and germline testing), the Global Cancer Diversity Atlas (population-scale genomic data repository), and OncoBuddy (patient support app). The company operates hospital-linked genomics laboratories across India, Dubai, Nepal, and Philippines, supported by patient initiatives like LuNGS Alliance and Hope Initiative. This platform-plus-services architecture enables clinicians to access both AI-driven insights and direct diagnostic testing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• OncoTwin: AI-powered precision oncology platform that creates digital twins of cancer patients by integrating genomic, pathology, radiology, and clinical data
• OncoBuddy
• Global Cancer Diversity Atlas (GCDA)
• LuNGS Alliance
• Hope Initiative

Products and services

• OncoTwin AI Platform AI-powered precision oncology platform that creates digital twins of cancer patients by integrating genomic, pathology, radiology, and clinical data. Delivers clinical decision support with patient twin matching, AI-enhanced molecular tumor boards, clinical trial optimization, and biomarker discovery for oncologists, hospitals, and pharmaceutical companies.
• Tissue Profiling (Solid Tumor Genomics) Comprehensive tumor DNA and RNA profiling from FFPE blocks that identifies actionable mutations, fusions, signatures, and resistance mechanisms to guide targeted, immunotherapy, and precision treatment decisions.
• Liquid Profiling (ctDNA Analysis) High-sensitivity circulating tumor DNA testing that detects actionable mutations, tracks treatment response, and overcomes tissue limitations through real-time, non-invasive genomic assessment for monitoring and treatment decisions.
• SoLiQ Dual-Source Genomics Combined tissue-liquid-germline approach that overcomes tumor heterogeneity, confirms true somatic variants, and delivers the most complete and clinically confident genomic picture for each patient.
• HRD Testing (PARPredict) Scar-based homologous recombination deficiency assay that measures genomic instability to identify HRD-positive tumors more accurately than BRCA-only testing, enabling confident PARP inhibitor therapy selection.
• Germline Cancer Risk & Treatment Insights Accurate hereditary cancer testing that identifies inherited risk variants, informs treatment sensitivity such as PARP inhibitor eligibility, and supports family counseling and preventive care.
• Global Cancer Diversity Atlas (GCDA) Population-scale genomic data repository with 30,000+ genomic profiles from 15+ underrepresented populations, covering 30+ rare and under-studied cancers and 70+ cancer types with integrated tumor, germline, liquid biopsy, clinical, and outcomes datasets.
• OncoBuddy Patient App Patient support platform and mobile app (available on Google Play and Apple App Store) that enables cancer patients and caregivers to share their cancer journey with other survivors, access community support, and receive affordable genetic testing assistance.

Quantifiable outcome

• 58% of 6,600+ lung cancer patients showed actionable mutations through LuNGS Alliance free testing
• +2 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core, minor and major.

• Bio Valley and Define Bio (P) Ltd.coreStrategic or Co-development Partner · 3 March 2026MoU to establish BioSphere Center of Excellence for Genomics and Next-Generation Sequencing at Andhra Pradesh MedTech Zone in Visakhapatnam. Initiative to strengthen India's genomic infrastructure and generate datasets reflecting India's genetic diversity.
• OwkincoreStrategic or Co-development Partner · 18 February 2026Collaboration to advance inclusive precision oncology research. Partnership aims to utilize diverse, large-scale datasets to enhance therapeutic research and address underrepresentation of Asian and Middle Eastern populations in pharmaceutical research.
• Caritas HospitalscoreStrategic or Co-development Partner · 1 June 2025Partnership with Caritas Hospitals to bring personalised cancer care to patients in Kerala, India. Aims to advance inclusive AI-driven cancer research using genomic solutions.
• AIIMS JammucoreStrategic or Co-development Partner · 22 January 2025MoU to launch Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu. Hope Initiative makes advanced genomic testing affordable and accessible for cancer patients.
• Innovate Life SciencescoreStrategic or Co-development Partner · 25 October 2024Partnership at Dubai Science Park to unlock genomics research for precision oncology in the Middle East region.
• Francis deSouzaminorOthers · 27 August 2024Former CEO of Illumina, a Silicon Valley tech veteran, joined 4baseCare's Advisory Board.
• IlluminacoreTechnology or IntegrationIllumina Accelerator Company - 4baseCare is backed by Illumina and operates as part of their accelerator program. Illumina provides sequencing technology and partnership for technology development.
• LuNGS Alliance (CRSF & 4baseCare)coreStrategic or Co-development PartnerCollaboration between oncologists, government hospitals, pharma companies (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Pfizer, Roche), Tata Capital, and 4baseCare providing free NGS tests to lung cancer patients. Provided 6,600+ tests across 700 cities.
• Max HealthcarecoreStrategic or Co-development PartnerHospital partnership for decentralized genomic testing infrastructure.
• Shankara HospitalcoreStrategic or Co-development PartnerHospital partnership for genomic testing services.
• Memorial Sloan Kettering Cancer Center (MSK)majorStrategic or Co-development PartnerOncoTwin platform selected for testing on MSK datasets through MSK iHub programme. Provides international validation for the AI platform.
• Lip-Bu TanminorOthersTech visionary and venture capitalist joined 4baseCare's advisory board.

Scale indicators15 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• MedGenome: India- and US-based genomics company offering NGS-based diagnostics and research services across oncology, reproductive health, and rare diseases. Most direct competitor to 4baseCare in Indian precision oncology.
• Strand Life Sciences: India-based genomics and bioinformatics company providing NGS diagnostics and clinical interpretation services. Directly comparable on genomic testing plus clinical decision support, with similar hospital-linked distribution model.
• Datar Cancer Genetics: India- and UK-based precision oncology company offering circulating tumor cell and cell-free DNA-based tests for cancer detection, treatment selection, and monitoring. Comparable oncology liquid biopsy and treatment-guidance offering.
• Caris Life Sciences: US-based precision oncology company offering comprehensive molecular profiling (tissue and liquid) plus an AI-driven clinical decision support platform (MI Profile). Closest global analogue to 4baseCare's combined testing + AI platform model.
• Tempus AI: US-based AI-powered precision medicine company combining large-scale genomic and clinical data with AI for oncology decision support. Comparable in combining NGS testing with AI platform and pharma R&D services.
• Guardant Health: US-based precision oncology company specializing in liquid biopsy (ctDNA) for therapy selection and monitoring. Direct overlap on liquid profiling tests (a core 4baseCare product) and broader oncology diagnostics.
• Personalis: US-based genomics company offering tumor profiling and immuno-oncology biomarker tests, with pharma services including clinical trial patient enrollment support. Comparable on NGS oncology + pharma R&D services model.
• Natera: US-based cell-free DNA testing company with growing oncology business (Signatera MRD test). Comparable on tumor-informed liquid biopsy and pharma services, though more oncology-adjacent than pure-play.

Broad incumbents

• Foundation Medicine (Roche): US-based NGS oncology profiling leader owned by Roche. Operates at significantly larger scale and provides similar comprehensive genomic profiling services, making it the dominant global incumbent against which 4baseCare competes for international pharma partnerships.

Others

• MGI Tech: China-based sequencing technology provider (part of BGI Group) and one of the underlying platforms 4baseCare uses alongside Illumina. Relevant as both an enabler and a potential competitor for low-cost NGS oncology in emerging markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@4baseCare
• LinkedInlinkedin.com/company/4basecare-genomics-private-limited
• Xx.com/4basecare
• Facebookfacebook.com/4basecare

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4baseCare